Drug Trial Radar · NCT07934472
A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
Dec 31, 2028
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess transfer of dapirolizumab pegol (DZP) across the placenta to infants from mothers who are administered DZP
Conditions
- Systemic Lupus Erythematosus
Interventions
Dapirolizumab pegol (DZP)Drug
Study participants will receive DZP at pre-specified timepoints
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma concentration of DZP in the infants at birthTime frame: At Birth during this study
- Plasma concentration of DZP in mothers at deliveryTime frame: At Delivery during this study
- Ratio between plasma concentration of DZP between the infants and mother at birth/deliveryTime frame: Infants: At Birth; Mothers: At Delivery during this study
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.